Medicxi Ventures Management (Jersey) Ltd
Long book
$981.8M
Q1 2026
Positions
4
Top-10 weight
100%
concentration
Last quarter
+6.0%
SPY +14.8%
Turnover
20%
of book per quarter
Strategy in plain words
auto-generated from filingsMedicxi Ventures Management (Jersey) Ltd is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $981.8M US long book across 4 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: CENTESSA PHARMACEUTICALS-ADR, NEWAMSTERDAM PHARMA CO NV, PHATHOM PHARMACEUTICALS INC, AURA BIOSCIENCES INC.
Over the last 9 quarters its long book ran on average 0.2pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.4%
Q2 2024
+35.3%
Q3 2024
-24.0%
Q4 2024
-22.6%
Q1 2025
+15.6%
Q2 2025
+32.0%
Q3 2025
+28.1%
Q4 2025
-19.1%
Q1 2026
+6.0%
Sector allocation
Healthcare 100%
Long book by quarter
What does Medicxi Ventures own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | Apr 21, 2026 | 4 | $981.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Jan 23, 2026 | 5 | $835.0M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Oct 17, 2025 | 5 | $744.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 8, 2025 | 5 | $427.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | Apr 11, 2025 | 5 | $437.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Jan 23, 2025 | 5 | $529.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Oct 15, 2024 | 4 | $528.9M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Jul 16, 2024 | 4 | $335.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Apr 15, 2024 | 5 | $449.2M | canonical | SEC ↗ |